Publication:
Effective Pseudomonas aeruginosa eradication in cystic fibrosis: multicenter study

dc.contributor.coauthorGuliyeva, Aynur
dc.contributor.coauthorYegit, Cansu Yilmaz
dc.contributor.coauthorYanaz, Muruvvet
dc.contributor.coauthorKalyoncu, Mine
dc.contributor.coauthorBalci, Merve Selcuk
dc.contributor.coauthorKarabulut, Seyda
dc.contributor.coauthorErgenekon, Almala Pinar
dc.contributor.coauthorTastan, Gamze
dc.contributor.coauthorUzunoglu, Burcu
dc.contributor.coauthorArslan, Huseyin
dc.contributor.coauthorYazan, Hakan
dc.contributor.coauthorBilgin, Gulay Bas
dc.contributor.coauthorSakalli, Ayse Ayzit Kilinc
dc.contributor.coauthorCakir, Erkan
dc.contributor.coauthorGirit, Saniye
dc.contributor.coauthorUyan, Zeynep Seda
dc.contributor.coauthorGokdemir, Yasemin
dc.contributor.coauthorEralp, Ela Erdem
dc.contributor.coauthorKarakoc, Fazilet
dc.contributor.coauthorKaradag, Bulent
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorKöstereli, Ebru
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2025-09-10T04:58:37Z
dc.date.available2025-09-09
dc.date.issued2025
dc.description.abstractBackground: Pseudomonas aeruginosa (PA) eradication is crucial in cystic fibrosis (CF) management. At our center, the success rate was 21.6%, prompting a revised eradication protocol to evaluate a new regimen.Methods: Cystic fibrosis patients with first-time PA detection were included. Nonmucoid PA cases received oral ciprofloxacin (3 weeks) and inhaled tobramycin (1 month). For mucoid PA or failed eradication, ciprofloxacin (3 weeks) and extended nebulized therapy (3 months, alternating tobramycin/colistin) were used. Intravenous antibiotics were given to unwell patients.Results: Among 109 CF patients (median age: 6 years), 79 (72.5%) achieved successful eradication. Oral ciprofloxacin and tobramycin inhalation were used in 66 patients (60.6%), extended nebulized therapy in 26 (23.8%), and intravenous antibiotics in 17(15.6%).Conclusion: The revised protocol achieved a high PA eradication rate in CF patients. Adapting treatment regimens based on PA characteristics and patient condition can optimize outcomes and improve CF management.
dc.description.fulltextNo
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.indexedbyPubMed
dc.description.indexedbyScopus
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuN/A
dc.identifier.doi10.1177/00099228251351699
dc.identifier.eissn1938-2707
dc.identifier.embargoNo
dc.identifier.endpage1588
dc.identifier.issn0009-9228
dc.identifier.issue11
dc.identifier.pubmed4057604
dc.identifier.quartileQ4
dc.identifier.scopus2-s2.0-105012547978
dc.identifier.startpage1581
dc.identifier.urihttps://doi.org/10.1177/00099228251351699
dc.identifier.urihttps://hdl.handle.net/20.500.14288/30337
dc.identifier.volume64
dc.identifier.wos001517976000001
dc.keywordsCystic fibrosis
dc.keywordsEradication
dc.keywordsPseudomonas aeruginosa
dc.language.isoeng
dc.publisherSage Publications Inc
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofClinical Pediatrics
dc.subjectPediatrics
dc.titleEffective Pseudomonas aeruginosa eradication in cystic fibrosis: multicenter study
dc.typeJournal Article
dspace.entity.typePublication
person.familyNameKöstereli
person.givenNameEbru
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files